Language Select
Varian Logo

VARIAN MEDICAL AFFAIRS

Engaging with clinicians around the world to exchange meaningful information and advance clinical research.
Advanced Search
  • Jun 21, 2018
    Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

    This trial assessed the addition of chemotherapy to Stage I (deeply invasive) grade 3 endometrial cancer and demonstrated improvement in failure free survival though no improvement in overall survival. This trial demonstrates that current practice patterns of EBRT alone for these patients is sufficient given additional toxicities associated with chemotherapy. Currently standard of care remains EBRT alone for this cohort of patients.

    PDF

    Journal & Date: Lancet Oncology, Volume 19, No. 3, p295–309, March 2018
    Key Institution:  International, multicenter
    Keywords: Endometrial cancer, Radiotherapy, Chemotherapy, Clinical Trial

FOR EDUCATIONAL AND SCIENTIFIC EXCHANGE ONLY – NOT FOR SALES OR PROMOTIONAL USE.

 

  • Follow Us

Production of any of the material contained herein in any format or media without the express written permission of Varian Medical Systems is prohibited.

Varian Logo